Call for Russian government to prevent drug shortages in domestic market

10 November 2020

Russian patients have called on the national government to take measures to prevent the ever-growing shortage of drugs in the domestic market, particular those that could be recommended for the treatment of COVID-19.

Currently the situation with drugs in Russia remains complex, which is primarily due to a very limited range in the majority of domestic pharmacies. Among the reasons of such shortages are primarily failures during labelling, as well as massive purchases of such drugs by local customers on a "just in case" basis.

At present, the most complex situation is observed in the case of levofloxacin and hydroxychloroquine – both of which are recommended by the Russian Ministry of Health for the treatment of COVID-19 - as well as various antibiotics and anticoagulants.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK